

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Remarks

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 35, 37, 38, 42, 45-48 and 51 are pending in the application. Claims 26-31, 36, 39, 40, 41, 43 and renumbered claims 49 and 50 are sought to be cancelled without prejudice to or disclaimer of the subject matter therein and with reservation to pursue the cancelled subject matter in the future.

Claims 35, 37 and 38 have been amended. Support for the amendments can be found in the specification at least at page 19, lines 16-21, page 20, lines 17-27 and page 39, lines 23-28. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Based on the above amendment and the following remarks, Applicant(s) respectfully request(s) that the Examiner reconsider all outstanding objections and rejections and that they be withdrawn.

I. Miscellaneous

Applicants note that the Examiner has renumbered claims 50-52 as claims 49-51.

II. Sequence Compliance

The Examiner has objected to the disclosure as not complying with 37 C.F.R. § 1.821-1.825 and requested that recited sequences in the claims be identified with SEQ ID Nos.

Applicants have amended the claims to insert SEQ ID Nos where deemed appropriate and believe that they are now in compliance with the sequence requirements. Withdrawal of the objections is respectfully requested.

III. *Rejection of the Claims Under 35 USC § 112.*

A. *Claims 35, 39-41, 43 and 45-46.*

In the Office Action at page 3, the Examiner rejected claims 35, 39-41, 43, 45 and 46 under 35 U.S.C. § 112, first paragraph. Applicants respectfully traverse this rejection.

Specifically, the Examiner stated that:

. . . the specification while being enabling for an isolated DNA molecule comprising a DNA sequence encoding the JAK3 kinase amino acid sequence of SEQ ID NO:16 capable of undergoing tyrosine phosphorylation by at least one cytokine or having cytokine receptor binding activity; the same wherein said molecule encodes a JAK3 kinase that is at least 80-99% homologous to the amino acid sequence of SEQ ID NO:16; an expression vector comprising any of said isolated DNA molecule [sic] and an isolated host cell comprising the same expression vector, does not reasonably provide enablement for other embodiments in the claims.

Applicants disagree that "other" embodiments of the claimed invention are not enabled.

In an attempt to support the argument for non-enablement, the Examiner refers to many alleged teachings in the art and states at page 5 of the Office Action that :

. . . the instant specification is not enabled for the broadly claimed invention for the following reasons. With regard to the breadth of the claims encompassing DNA sequence encoding any and all JAK3 kinase or JAK3 kinase peptide, apart from the disclosure of a mouse cDNA sequence encoding JAK3 kinase of the amino acid sequence of SEQ ID NO:16, the specification fails to teach specifically other cDNA sequences encoding non-mouse Jak3 kinases. For

examples, the instant specification does not teach the cloning, isolation and characterization of cDNA sequences encoding for human JAK3 kinase of Kawamura et al. (Proc. Natl. Acad. Sci. 91:6374-6378, 1994), Civin et al. (U.S. Patent No. 5,705,625 with the effective filing date of December 15, 1994), Rane & Reddy (Oncogene 9:2415-2423, 1994) or that encoding for rat JAK3 kinase of Takahashi & Shirasawa (FEBS Letters 342:124-128, 1994) and their derived JAK3 kinase peptides.

The Examiner refers to the rejected claims as "encompassing *any and all* JAK3 kinase or JAK3 kinase peptides." This is an incorrect basis for rejecting the claims for at least two reasons. First, Applicants are not claiming "any and all" JAK3 kinase or JAK3 kinase peptides. Rather the claims are drawn to Jak3 kinase peptides that 1) have Jak kinase activity and 2) undergo phosphorylation by at least one cytokine. Further, Applicants have amended claim 35 to add the limitation that the isolated DNA comprise a sequence of SEQ ID NO:16 that encodes at least 400 amino acids of a Jak kinase peptide.

Second, the Examiner appears to base the rejection, at least in part, on the argument that the "specification fails to teach *specifically* other cDNA sequences encoding non-mouse Jak3 kinases." There is no requirement under 35 U.S.C. § 112, first paragraph that requires the specification to "specifically" teach *every* embodiment of a claimed invention. Applicants are merely required to teach one of skill in the art how to make and use the claimed invention without undue experimentation. This, applicants have done.

Merely because others in the art, after the effective filing date of the invention, may have obtained JAK3 kinases whose sequences are not specifically provided in the specification, this does not support an argument for non-enablement. In fact, it supports the opposite position, i.e. that the claimed invention is enabled. The art cited by the Examiner establishes that one of skill in the art would have been capable of obtaining different

embodiments of the invention based either on information present in the application alone or in combination with what such an artisan would have been expected to know as of the application's filing date. Clearly, this establishes that sufficient teachings were available to the skilled artisan to practice the invention without undue experimentation. Merely because certain embodiments may not have been "specifically" taught in the specification, this does not establish lack of enablement.

Various embodiments of the claimed invention are taught in the specification. For example, using the specification either alone or in conjunction with the art there is sufficient guidance for using a Jak kinase cDNA of one species to obtain the corresponding Jak cDNA of another species (see the alignment comparison in Figure 6.) Further evidence of this can be seen in Takahashi *et al.*, *FEBS Letters* 342:124-128 (1994) using Jak3 cDNA to detect the Jak3 gene in human, mouse, chicken, snake and frog (*See* page 126, col. 2 of Takahashi). Takahashi, however, while cited by the Examiner is not prior art. (*See* details in rebuttal of the § 102(a) rejection below).

At the bottom of page 3, the Examiner stated that, "the specification fails to teach specifically which JAK3 kinase peptide, which 15 to 400 amino acid fragment, which 5 to 335 amino acid fragment." This aspect of the rejection is now moot. The claims reciting these ranges have been cancelled. The Examiner's attention, however, is directed to the fact that amended claim 35 now recites "at least" 400 amino acid limitation. Such a fragment represents a significant portion of the complete sequence and one of skill in the art should have no difficulty in selecting the appropriate portion of the molecule to use in the claimed invention.

The Examiner also stated beginning at page 6, line 6 that the "claims do not even recite any critical elements involved in JAK kinase activity or cytokine receptor binding activity that the encoded JAK kinase peptides need to possess." Applicants fail to understand how recitation of a limitation to require a JAK kinase peptide to undergo tyrosine phosphorylation or have cytokine receptor activity fails to provide a critical element to the claims. In any event, there nothing under 35 U.S.C. § 112, first paragraph requires Applicants to explain how an invention works as the Examiner appears to be requesting by reference to "critical elements" of the invention. It is sufficient to merely provide one of skill in the art with sufficient information to make and use the claimed invention without undue experimentation. This, Applicants have done. Regardless, in an attempt to expedite prosecution, Applicants have further added a size limitation to the amino acid sequence encoded and reference to a specific group of cytokines involved in tyrosine phosphorylation to claim 35. Therefore, this aspect of the rejection is overcome.

The Examiner further stated at page 6, beginning at line 8 of the office action that:

It is well recognized in the art, any modification (even a "conservative" substitution) to a critical structural region of a protein is likely to significantly alter its functional properties, let alone any extensive deletion or fragmentation or substitution or insertion. The present disclosure offers no guidance as to which regions of the JAK molecule would be tolerant of alteration or fragmentation and which would not, which "particular" amino acid changes at which position and at which combinations, such that the kinase peptides possessing the desired activities as claimed could be obtained. There is a high degree of unpredictability associated with the make [sic] and use of the claimed embodiment. In discussing peptide hormones, Rudinger has stated that "The significance of particular amino acids and sequences for different aspects of biological activity can not be predicted a priori but must be determined from case to case by painstaking experimental study (Page 6, first sentence of Conclusions In J.A. Parsons, ed. "Peptide hormones", University Park Press, 1976). This

unpredictability is further underscored by the fact that the relationship between the sequence of a peptide and its tertiary structure (or its activity) is not well understood and is not predictable (Ngo et al., In K. Merz et al., ed. "The protein folding problem and tertiary structure prediction", Birkhauser, 1994, 491-495). Moreover, the physiological art is recognized as unpredictable (MPEP 2164.03).

Applicants respectfully disagree. In any event, this aspect of the rejection is now moot since the claims are now limited by recitation to "at least 400 amino acids of a Jak 3 kinase peptide." Based on all of the above, this rejection is overcome and should be withdrawn.

B. Claims 26, 30-31, 35-37, 40, 43 and 45-46

At page 7 of the Office Action, the Examiner rejected claims 26, 30-31, 35-37, 40, 43 and 45-46 under 35 U.S.C. § 112, first paragraph as allegedly containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. Applicants respectfully traverse this rejection.

The Examiner further argues that "the skilled artisan cannot envision the detailed structure of the broadly claimed isolated DNA molecule comprising a DNA sequence encoding a JAK kinase or a JAK kinase peptide. . ." as well as vectors and host cells containing the claimed DNA. This is now moot because one wishing to practice the invention would know from the amended claim language that the structure of the claimed invention will comprise a DNA sequence encoding at least 400 amino acids found in SEQ. ID. No:16. This clearly allows one of skill in the art to envisage the claimed invention and know that Applicants had possession of the invention as of the filing date. Therefore, based on the amended claim language, this rejection should be withdrawn.

IV. Rejection of Claims 28-29, 31 and 37-41 Under 35 U.S.C. § 112, Second Paragraph

At page 10 of the Office Action, the Examiner rejected claims 28-29, 31 and 37-41 under 35 U.S.C. 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as the invention. Applicants respectfully traverse this rejection.

The rejection, however, is moot as it applies to claims 28-29, 31 and 37. These claims have been cancelled without prejudice or disclaimer.

The Examiner considered claim 38 indefinite because "it is unclear which polypeptides recited in the claim corresponds to which amino acid sequences listed in Figure 6. In addition, the amino acid sequences listed in the claim are not identified by any SEQ ID NO, it is truly confusing." Claim 38 is dependent on claim 35 that now makes reference to SEQ ID NO:16. The addition of SEQ ID No:16 to claim 35 renders moot the rejection.

The Examiner considered claims 39 and 41 unclear because of the recitation "corresponding." This rejection is moot because claims 39 and 41 have been cancelled

In claim 40, the Examiner alleged that the claim was indefinite. Applicants have cancelled this claim. Therefore, the rejection is moot.

Based on all of the above, the rejection of the claims under 35 U.S.C. § 112, second paragraph should be withdrawn.

V. Rejection of the Claims Under 35 U.S.C. § 102(b).

A. Claims 26 and 28

At page 12 of the Office Action, the Examiner rejected claims 26 and 28 under 35

U.S.C. § 102(b) as allegedly being anticipated by Harpur et al. (Oncogene 7:1347-1353, 1992) or Firmbach-Kraft et al. (Oncogene 5:1329-1336, 1990). Applicants respectfully traverse this rejection. Solely in an effort to expedite prosecution, however, and without acquiescing in the propriety of the rejection, Applicants have cancelled claims 26 and 28 without prejudice or disclaimer. Therefore, this rejection is now moot.

B. Claim 26

At page 13 of the Office Action the Examiner rejected claim 26 under 35 U.S.C. § 102 (b) as allegedly anticipated by Wilks et al. (Mol. Cell. Biol. 11: 2057-2065, 1991). Applicants respectfully traverse this rejection. Solely in an effort to expedite prosecution, however, and without acquiescing in the propriety of the rejection, Applicants have cancelled claims 28 without prejudice or disclaimer. Therefore, this rejection is now moot.

VI. Rejection of Claims 26, 28, and 29 Under 35 U.S.C. § 102(e)

In the Office Action at page 13, the Examiner rejected claims 26, 28 and 29 under 35 U.S.C. § 102(e) as being anticipated by Wilks et al. (U.S. Patent No. 5,658,791 with the effective filing date of June 30, 1993). Applicants respectfully traverse this rejection. Solely in an effort to expedite prosecution, however, and without acquiescing in the propriety of the rejection, Applicants have cancelled claims 26, 28 and 29 without prejudice or disclaimer. Therefore, this rejection is now moot.

VII. Rejection of the Claims Under 35 U.S.C. § 102(a)

A. Claims 35, 39-42, 47, 49-51.

In the Office Action at page 14, the Examiner rejected claims 35, 39-42, 47 and 49-51 under 35 U.S.C. § 102(a) as allegedly being anticipated by Kawamura et al. (Proc. Natl. Acad. Sci. 91:6374-6378, 1994 - hereinafter "Kawamura") or Takahashi & Shirasawa (FEBS Letters 342:124-128, 1994 - hereinafter "Takahashi"). Applicants respectfully traverse this rejection.

Solely to expedite prosecution of the application and reserving the right to rebut the rejection on the merits in the future, Applicants submit herewith declarations under 37 C.F.R. § 1.131 from the inventors Drs. Bruce Witthuhn (**Exhibit A**), James Ihle (**Exhibit B**) and Ollie Silvenoinen (**Exhibit C**). Previously, the same set of Exhibits were used for all three inventors and therefore Applicants are submitting only one set of Exhibits with the declarations. The declarations with exhibits were previously submitted in related U.S. Application No:08/665,574 (Now U.S. Patent No: 6,136,595). The declaration addresses embodiments of the inventions related to DNA molecules comprising a DNA sequence encoding an amino acid sequence of a Jak3 kinase peptide and a vector or host comprising said DNA. This Declaration establishes that prior to April 1994, Applicants had in their possession, a full-length clone containing the mJak3 sequence (*See* Paragraph 10 of the Declaration). Additionally, paragraphs 4 and 7 of the declaration provide evidence that Applicants were in possession of partial clones of the Jak kinase molecule.

The undersigned had previously been informed by the publisher of Takahashi that it published between April 1 and April 15, 1994. Further, the undersigned has been informed

by the publisher of Kawamura that it published July 5, 1994. Therefore, based at least on the § 1.131 declaration, Applicants' invention predates both Takahashi. and Kawamura. As such, neither Takahashi nor Kawamura is proper prior art under § 102(a), this rejection of the claims is overcome and should be withdrawn.

B. Claims 43 and 48.

At page 16, the Examiner rejected claims 43 and 48 under 35 U.S.C. 102(a) as allegedly being anticipated by Kawamura or Takahashi. Applicants respectfully traverse this rejection.

As noted above, the cited art was not published before Applicants' invention and is not prior art under 35 U.S.C. § 102(a). Therefore, this rejection is overcome and should be withdrawn.

VIII. Rejection of the Claims Under 35 U.S.C. § 103(a)

A. Claims 26, 30 and 31

At page 18 of the Office Action, the Examiner rejected claims 26, 30 and 31 under 35 U.S.C. 103(a) as allegedly being unpatentable over Harpur et al. (Oncogene 7:1347-1353, 1992) or Wilks et al. (Mol. Cell. Biol. 11:2057-2065, 1991). Applicants respectfully traverse this rejection. The rejection is now moot because Applicants have cancelled the claims without prejudice or disclaimer.

B. Claims 35 and 45-56

At page 19, the Examiner rejected claims 35 and 45-46 under 35 U.S.C. 103(a) as allegedly being unpatentable over Kawamura or Takahashi. Applicants respectfully traverse this rejection.

As indicated above with regard to the § 102(a) rejection, neither Kawamura nor Takahashi is prior art to the claimed invention. Therefore, this rejection is overcome and should be withdrawn.

IX. Rejection of Claims 26, 30, 35-37, 45-47 and 49-51 Obviousness-Type Double Patenting

In the Office Action at page 21, the Examiner rejected claims 26, 30, 35-37, 39-42, 45-47 and 49-51 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 6,136,595. Applicants respectfully traverse this rejection, however, request that it be held in abeyance until the claims are otherwise in condition for allowance.

Conclusion

All of the stated grounds of objection and rejection have been properly traversed, accommodated, or rendered moot. Applicant(s) therefore respectfully request(s) that the Examiner reconsider all presently outstanding objections and rejections and that they be withdrawn. Applicant(s) believe that a full and complete reply has been made to the outstanding Office Action and, as such, the present application is in condition for allowance.

If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (202) 371-2589.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lawrence B. Bugaisky
Attorney for Applicants
Registration No. 35,086

Date: August 28, 2007

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Version with markings to show changes made

Substitute the following claim 35 for the pending claim 36.

35. (Once Amended) An isolated DNA molecule comprising a DNA sequence encoding [Jak3 kinase or a] at least 400 amino acids of a Jak3 kinase peptide of SEQ ID NO:16, wherein said peptide has Jak kinase activity and undergoes tyrosine phosphorylation by at least one cytokine selected from the group consisting of IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-11, OSM, LIF, G-CSF, EPO, IFN- γ and GM-CSF.

Substitute the following claim 36 for the pending claim 36.

36. (Once Amended) The isolated DNA molecule of [claims 27] claim 35 wherein said molecule encodes a polypeptide having at least one conservative amino acid substitution.

Substitute the following claim 38 for the pending claim 38.

38. (Once Amended) The isolated DNA molecule of claim 35 comprising a 1500 nucleotide base DNA sequence [encoding a polypeptide selected from the group consisting of amino acids 15-1500, 15-1009, 15-1006, 30-600 and 90-1500] of Figure 6 encoding an amino acid sequence of SEQ ID NO: 16.

RECEIVED

AUG 30 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

IHLE *et al.*

Appl. No. 08/665,574

Filed: June 18, 1996

For: **Jak Kinases and Regulation of
Cytokine Signal Transduction**



Art Unit: 1819


Examiner: Hauda, K.

Atty. Docket: 0656.0370002/SLF/LBB

**Declaration of Bruce A. Witthuhn and James N. Ihle
Under 37 C.F.R. § 1.131**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:



1. We, Bruce Witthuhn and James Ihle state that we are two of the named applicants of the above-captioned application and are co-inventors of the subject matter described and claimed therein.
2. Prior to April 1994, we and Dr. Ollie Silvennoinen reduced to practice in the U.S., the invention of the above-captioned application.
3. Said reduction to practice concerns at least those embodiments of the claimed invention that are related to DNA molecules comprising a DNA sequence encoding an amino acid sequence of a Jak3 kinase peptide and a vector or host comprising said DNA.
4. Prior to April 1994, two clones were obtained that were labeled as B1.1 and B3.1. *In vitro* translation experiments with T3 and T7 primers indicated that clone B3.1 was a partial clone and B1.1 was a full-length clone corresponding in length to other previously identified Jaks. *See* the third lane labeled as B1.1 T₃. (**Exhibit A**)
5. Following additional analysis completed prior to April 1994 it was established that the mJak3 expressed product could be competed out with a specific peptide to Jak3, thereby further supporting the assumption that a full length clone had been obtained. For example, *See Exhibit B*.

7. Upon information and belief, prior to April 1994, partial sequencing of subclones from B1.1 was completed by Dr. Silvennoinen. (Exhibit C).

8. Following the partial sequencing of the B1.1 subclones, a full length mJak3 sequence of clone B1.1. was obtained prior to April, 1994. A working copy of this sequence is provided as Exhibit D.

9. Upon information and belief, prior to April 1994 a figure containing the complete amino acid sequence encoded by the full-length DNA of mJak3 was prepared by the Biomedical Communications Department at St. Jude. (Exhibit E).

10. All of the above results demonstrate that prior to April 1994, a full-length clone containing the mJak3 sequence had been obtained.

11. The attached are true and accurate photocopies (with dates blanked out) of pages taken from the notebooks or other sources of the inventors or those individuals supervised by the inventors.

12. We further state that all statements made are to our knowledge true and that all statements made on information and belief are believed to be true and further that willful false statements and the like are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the U.S. Code and may jeopardize the validity of the application or any patent issuing thereon.

2/22/99
Date

Bruce A. Witthuhn
Bruce A. Witthuhn

Date

James N. Ihle

1ul DNA
 1ul Ribosin
 2ul reaction buffer
 1ul polymerase
 4ul 35T_{trans}
 25ul Rabbit Ret Lys
 1ul A. Acid mix
 15ul H₂O

| | | | |
|---------|---------|------|------|
| B1.1 | B3.1 | JAK1 | JAK2 |
| T3 : T7 | T3 : T7 | T3 | T3 |

| | | | |
|----|----|-------|-------|
| J1 | J2 | B1.1 | B2.1 |
| | | T3 T7 | T3 T7 |

IP 5ul of B1.1 with 10ul 3015
 3029
 3030

| | | |
|-------------------|-------------------|--------------------|
| | J2 | TK5 |
| TCL 211 1065 3012 | TCL 214 1067 3013 | TCL 3015 3029 3030 |

Tube 3013 popped open when
 boiling - reaction filled with H₂O
 loaded \approx 100ul on gel of \approx 400ul

ARD

KODAK SAFETY FILM ARD

TakIT₃

TakZT₃

B1.1T₃

B1.1T₇

B3.1T₃

B3.1T₇

KODAK SAFETY FILM ARD

In vitro translation

- ✓ 1ul DNA
- ✓ 1ul RNasin
- ✓ 2ul reaction buffer
- ✓ 1ul a.a. - M
- 5ul ~~SS~~ trans
- 1ul Polymerase
- 14ul H₂O
- 25ul TnT reticulocyte

JAK1 T₃
 JAK2 T₃
 TK5 B1.1 T₃
 ERLF from B-cell T₇

Competition

TK5 B1.1
translation

- 10ul 3015 + —
- 10ul 3015 + 2ul 10ng/ul TK5-1
- + 2ul " TK5-3
- 10ul 3029 + —
- 10ul 3030 + —
- + 2ul 10ng/ul TK5-1
- 5ul 1067
- 5ul 3012

JAK1

- 211 5ul
- 3012 5ul
- 1065 5ul
- 3015 10ul

Load gel
 TEL 3015
 J1 J2 J3
 3015 3015 3015
 5.1 5.3

3015 3029 3030
 1067 3012
 mistake J1 B11

JAK2

- 214 5ul
- 1067 5ul
- 3013 5ul
- 3015 10ul

Load gel
 TEL
 211 3012 1065 3015 J1 J2 J3

214 1067 3013 3015

Fluorograph corresponding to
in vitro translation done by
baw on

TCL
J1 J2 TK5

TK5 in vitro translation
↑

Except this lane -
mistakenly loaded as
TK5/3012 if
actually J1 3012 if

3015 PI

3019

3019/5.1

3015/5.3

3029





3030

1067



3012


in vitro translation

DQW



in vitro
law of translation





5410522

DyeTerminator{AnyPrimer}

Lane 22

Signal: G:139 A:69 T:59 C:32

Points 631 to 5937 Base 1: 631

INST FILE 707173


B.1.1+S2a

For Ollie Silvermoinq/111c

Page 1 of 2

X: 0 10 6897 Y: 0 10 1200

Spacing: 10.00



Model 373A

Version 1.2.1

5410S20

DyeTerminator{AnyPrimer}

Lane 20

Signal: G:25 A:34 T:35 C:16

For Ollie Silvernoinen/Hile





B.1.1+51a

Points 0 to 5937 Base 1: 0
INST FILE 707173

X: 0 10 6347 Y: 0 10 1200

Spacing: -12.00

Page 1 of 2



... 2 separate searches.
... searches of the latest release of GenBank and use
... BLAST program or homology searches of newly released sequences.

Use SEARCHNCBI and DENCBI to search for and retrieve new sequences.

Documentation for the NCBI BLAST and other NCBI programs is in the newsgroup
stjude.mbcf. If you need any assistance getting started or using any of the
NCBI programs please call the MBCF at ext. 2385 or ext 689.

SEQ:

>>> Closing output file.
>>> At connection #0 (mbcf.stjude.org)

type cc.rec
> 0 <
0! 0 IntelliGenetics
> 0 <

SEQ - Sequence Analysis System
Version 5.4

SEQ: translate

Default is translation in 3-letter code in one frame.

TRANSLATE: three

TRANSLATE [Three-Frame]: run

Name or number of the sequences to be analyzed (<CR> when done).

Sequence: 3

Sequence:

Would you like the non-coding strand of each sequence to be shown? (<CR>=No)

B1.1E-X

27
ATG GCACCT CCA AGT GAG GAG ACA CCT CTG ATC CCT CAG CGC TCT TGC AGC CTC
MET Ala Pro Pro Ser Glu Glu Thr Pro Leu Ile Pro Glu Arg Ser Cys Ser Leu
Trp His Leu Gln Val Arg Arg His Leu Ser Leu Ser Ala Leu Ala Ala Ser
Gly Thr Ser Lys Gly Asp Thr Ser Asp Pro Ser Ala Leu Leu Gln Pro Leu

81
TCA TCC TTA GAG GCA GAA GGC TTG CAT GTG CTC CTT CCT TCC GAG GAA CTC
Ser Ser Ser Glu Ala Gly Ala Leu His Val Leu Leu Pro Pro Arg Phe Pro Gly
His Pro Gln Arg Gln Glu Pro Cys MET Cys Ser Phe Leu Pro Gly Asp Leu Gly
Ile Leu Arg Gly Arg Ser Leu Ala Cys Ala Pro Ser Ser Pro Gly Thr Trp Ala

135
CCT CCC CAG CGA TTG TCA TTC TCT TTT GGG GAC TAC TTG GCT GAG GAT TTA TGT
Pro Pro Gln Arg Leu Ser Phe Ser Phe Gly Asp Tyr Leu Ala Glu Asp Leu Cys
Leu Pro Ser Ser Cys His Ser Leu Leu Gly Thr Thr Thr Thr Thr Thr Thr Thr

162

52a (217) 188 216

Pro CCA TGT GGT AAG GCG TGT GGG ATC CTG GCT GTT TAT CAT TCG CTT TTC GGT
Val Arg Ala Ala Lys Ala Cys Gly Ile Leu Pro Val Tyr His Ser Leu Phe Ala
Cys Gln Leu Pro Arg Pro Val Gly Ser Cys Leu Phe Ile Ile Arg Phe Ser Leu
Ala Ser Cys Gln Gly Leu Trp Asp Pro Ala Cys Leu Ser Phe Ala Phe Arg Ser

CTG GGC ACT GAG GAC TTC TGT TGC TGG TTT CCC CCA AGC CAC ATC TTC TGC ATA
Leu Ala Thr Gln Asp Phe Ser Cys Trp Phe Pro Pro Ser His Ile Phe Cys Ile
Trp Pro Leu Arg Thr Ser Leu Ala Gly Phe Pro Gln Ala Thr Ser Ser Ala
Gly His Gly Leu Leu Leu Leu Val Ser Pro Lys Pro His Leu Leu His Arg

GAG GAC GTG GAC ACT CAA GTC TTG GTC TAC AGG CTA CGC TTT TAT TTC CCT GAC
Glu Asp Val Asp Thr Gln Val Leu Val Tyr Arg Leu Arg Phe Tyr Phe Pro Asp
Arg Thr Trp Thr Leu Lys Ser Trp Ser Thr Gly Tyr Ala Phe Ile Ser Leu Thr
Gly Arg Gly His Ser Ser Leu Gly Leu Gln Ala Thr Leu Leu Phe Pro Leu

TGG TTT GGG CTG GAG ACA TGT CAC CGC TTT GGG CTG CGC AAA GAT TTG ACC AGT
Trp Phe Gly Leu Gln Thr Cys His Arg Phe Gly Leu Arg Lys Asp Leu Thr Ser
Gly Leu Gly Trp Arg His Val Thr Ala Leu Gly Cys Ala Lys Ile Pro Val
Val Trp Ala Gly Asp MET Ser Pro Leu Trp Ala Ala Gln Arg Phe Asp Gln Cys

GCC ATC CTT GAC TTA CAT GTT TTA GAA CAT CTC TTT OCT CAG CAC CGC AGT GAC
Ala Ile Leu Asp Leu His Val Leu Gln His Leu Phe Ala Gln His Arg Ser Asp
Pro Ser Leu Thr Tyr MET Phe Asn Ile Ser Leu Leu Ser Thr Ala Val Thr
His Pro Leu Thr Cys Phe Arg Thr Ser Leu Cys Ser Ala Pro Gln Pro

CTG GTG AGT GGG CGC CTC CCG GTG GGC CTT AGC ATG AAG GAG CAG GGA GAG TTC
Leu Val Ser Gly Arg Leu Pro Val Gly Leu Ser MET Lys Glu Gln Gly Glu Phe
Trp Val Gly Ala Ser Arg Trp Ala Leu Ala Arg Ser Arg Glu Ser Ser
Gly Glu Trp Ala Pro Pro Gly Gly Pro His Glu Gly Ala Gly Arg Val Pro

CTG AGC CTG GCC GTG CTG GAC TTG GGC CAG ATG GGT GGT GAG GAG GCG CAG CGC
Leu Ser Leu Ala Val Leu Asp Leu Ala Gln MET Ala Arg Glu Gln Ala Gln Arg
Ala Trp Pro Cys Trp Thr Trp Pro Arg Trp Leu Val Ser Arg Pro Ser Ala
Glu Pro Gly Arg Ala Gly Leu Gly Pro Asp Gly Ser Ala Gly Pro Ala Pro

CCA GGA GAG CTG CTG AAG ACG GTC AGT TAC AAA GCC TGT CTG CCG CCC AGC CTG
Pro Gly Glu Leu Leu Lys Thr Val Ser Tyr Lys Ala Cys Leu Pro Pro Ser Leu
Gln Glu Ser Cys Arg Arg Ser Val Thr Lys Pro Val Cys Arg Pro Ala Cys
Arg Arg Ala Ala Gln Asp Gly Gln Leu Gln Ser Leu Ser Ala Ala Gln Pro Ala

CGC GAT GTG ATC CAG GGC CAG AAC TTC GTG ACA CGC AGG CGC ATC CGC AGG ACC
Arg Asp Val Ile Gln Gly Gln Asn Phe Val Thr Arg Arg Arg Ile Arg Arg Thr
Ala MET Ser Arg Ala Arg Thr Ser His Ala Gly Ala Ser Ala Gly Pro
Arg Cys Asp Pro Gly Pro Glu Leu Arg Asp Thr Gln Ala His Pro Gln Asp Arg

GTG GTC TTG GCG TCG TGG TGC TGT TCC TTC
Val Val Leu Ala Cys Ser Arg Val Val Ala Cys Gln Ala Asp Val Arg Ala His
Trp Ser Trp Arg Ala Ala Val Trp Ser Pro Ala Arg Pro Thr Tyr Ala Leu MET
Gly Leu Gly Val Gln Pro Cys Gly Arg Leu Pro Gly Arg Arg Thr Arg Ser Trp
CTG CTG CCG TGT GGT CCG CTG

729 750
GGC GAA GTA TAT TCT GAC CTG GAG CCG GTA CAT CCA GCG GCC ACC ACC GAG ACC
Gly Gln Val Tyr Ser Asp Leu Glu Arg Leu His Pro Ala Ala Thr Thr Glu Thr
Ala Lys Tyr Ile Leu Thr Trp Ser Gly Tyr Ile Gln Arg Pro Pro Pro Arg Phe
Pro Ser Ile Phe Pro Gly Ala Ala Thr Ser Ser Gly His His Arg Asp Leu

783 810
TTC CGT GTG GGG CTC CCG GGC GCC CAG GAG GAG CCG GGG CTT CTG CGT GTG GCA
Phe Arg Val Gly Leu Pro Gly Ala Gln Glu Glu Pro Gly Leu Leu Arg Val Ala
Ser Val Trp Gly Ser Arg Ala Pro Arg Arg Ser Arg Gly Phe Cys Val Trp Gln
Pro Cys Gly Ala Pro Gly Arg Pro Gly Gly Ala Gly Ala Ser Ala Cys Gly Arg

834 864
GGG GAC AAC GGC ATC CCG GGA CTC CCG GAC CAG GAG CTT TTC CAG ACC TTC TGT
Gly Asp Asn Gly Ile Ser Arg Leu Arg Asp Gln Glu Leu Phe Gln Thr Phe Cys
Gly Thr Thr Ala Ser Arg Asp Ser Gly Thr Arg Ser Phe Ser Arg Pro Ser Val
Gly Gln Arg His Leu Glu Thr Pro Gly Pro Gly Ala Phe Pro Asp Leu Leu

891 918
GAC TTT CCG GAA ATC GTG GAT GTS AGC ATC AAT CAG GCC CCA CGT GTG GTC CCG
Asp Phe Pro Glu Ile Val Asp Val Ser Ile Asn Gln Ala Pro Arg Val Val Arg
Thr Phe Arg Lys Ser Trp MET Ser Ala Ser Ile Arg Pro His Val Trp Ser Gly
Leu Ser Gly Asn Arg Gly Cys Gln His Gln Ser Gly Pro Thr Cys Gly Pro Ala

945 972
CAG GGA GGA GCG GCT GGT CAG TGT CAG CAG GAT GGA CCG CCA CAT CCT GGA
Gln Gly Ala Pro Ala Gly His Cys His Gln Asp Gly Arg Pro His Pro Gly Cys
Arg Glu His Arg Leu Val Thr Val Thr Arg MET Asp Gly His Ile Leu Asp Ala
Gly Ser Thr Gly Trp Ser Leu Ser Pro Gly Trp Thr Ala Thr Ser Trp MET Arg

999 1026
GGA GTT TCC GGG GCT GCC TGA GGC GCT GTC TTT CGT GGC CCT CGT GGA TGG GTA
Gly Val Ser Gly Ala Ala Gly Ala Val Phe Arg Gly Pro Arg Gly Trp Val
Glu Phe Pro Gly Leu Pro Glu Ala Leu Ser Phe Val Ala Leu Val Asp Gly Tyr
Ser Phe Abg Gly Cys Leu Arg Arg Cys Leu Ser Trp Pro Ser Trp MET Gly Thr

1053 1080
CTT CCG CCT GAT CTG CGA CTC CAG GCA TTA TTT CTG CAA GGA GGT GGC GCC GCC
Leu Pro Pro Asp Leu Arg Leu Gln Ala Leu Phe Leu Gln Gly Gly Gly Ala Ala
Phe Arg Leu Ile Cys Asp Ser Arg His Tyr Phe Cys Lys Glu Val Ala Pro Pro
Ser Ala Ser Ala Thr Pro Gly Ile Ile Ser Ala Arg Arg Trp Arg Arg Gln

1107 1134
AGG CTG CTG GAG GAG GAG GCG GAC GTG TGC CAT GGA CC ATC ACC TTA GAT TTT
Arg Leu Leu Glu Glu Glu Ala Asp Val Cys His Gly Pro Ile Thr Leu Asp Phe
Gly Cys Trp Arg Arg Arg Arg Thr Cys Ala MET Asp Pro Ser Arg Thr Leu
Ala Ala Gly Gly Gly Gly Gly Arg Val Pro Trp Thr His His Val Arg Leu Cys

1161 1188
GCC ATC CAC GAA GGT TGA GGG CCG GTC CCG GGT CCA GGC ACC TAT ATT CTC ACC

His Pro Pro Ser Leu Lys Ala Ala Ala Pro Ser Arg His Leu Tyr Ser Pro Pro

1215 1242
CGC AGC CCG CAG GAC TAT GAC AGC TTT CTT CTT ACC GCC TGC GTC CAG ACT CCT
Arg Ser Pro Gln Asp Tyr Asp Ser Phe Leu Leu Thr Ala Cys Val Gln Thr Pro
Ala Ala Arg Arg Thr MET Thr Ala Phe Phe Leu Pro Pro Ala Ser Arg Leu Leu
Gln Pro Ala Gly Leu Gln Leu Ser Ser Tyr Arg Leu Arg Pro Asp Ser Ser

1269 1296
CTT GGC CCC GAC TAC AAG GGC TGC CTC ATC CGC CAG GAC CCA GCG GCG CTT TCT
Leu Gly Pro Asp Tyr Lys Gly Cys Leu Ile Arg Gln Asp Pro Ala Gly Leu Ser
Leu Ala Pro Thr Thr Arg Ala Ala Ser Ser Ala Arg Thr Gln Arg Gly Phe Leu
Trp Pro Arg Leu Gln Gly Leu Pro His Pro Pro Gly Pro Ser Gly Ala Phe Ser

1323 1350
CCC TGG TTG CTT CAG CCA GCC CCA CAG AAG CTG CGG GAG CTG CTT GCA GCC TGC
Pro Trp Leu Pro Gln Pro Ala Pro Gln Lys Leu Arg Glu Leu Leu Ala Ala Cys
Pro Gly Cys Leu Ser Gln Pro His Arg Ser Cys Gly Ser Cys Leu Gln Pro Ala
Leu Val Ala Ser Ala Ser Pro Thr Glu Ala Ala Gly Ala Ala Cys Ser Leu Leu

1377 1404
TGG AAT TCT GGG CTG CGA CTA GAC GGT GCT GCC CTG TAC CTA ACA TCC CCG CGC
Trp Asn Ser Gly Leu Arg Val Asp Gly Ala Ala Leu Tyr Leu Thr Ser Arg Arg
Gly Ile Leu Gly Cys Glu Thr Val Leu Pro Cys Thr His Pro Gly Ala
Glu Phe Trp Ala Ala Ser Arg Arg Cys Cys Pro Val Pro Asn Ile Pro Ala Leu

1431 1458
TTC CAG ACC CAA GGA AAA GTC CAA TTG ATC GTG GTG CGA AGG CTG CAC CCG GCC
Ser Gln Thr Gln Gly Lys Val Gln Leu Ile Val Val Arg Arg Leu His Arg Ala
Pro Arg Pro Lys Glu Lys Ser Asn Ser Trp Cys Glu Gly Cys Thr Ala Pro
Pro Asp Pro Arg Lys Ser Pro Ile Asp Arg Gly Ala Lys Ala Ala Pro Arg Leu

1485 1512
TTC CCG GCT GCT CCC CGT CCT GCT GTG CGC TGA CAC AGC TGA GCT TCC ACA CAA
Ser Pro Ala Ala Pro Arg Pro Ala Val Arg His Ser Ala Ser Thr Gln
Pro Arg Leu Leu Pro Val Leu Leu Cys Ala Asp Thr Ala Glu Leu Pro His Asn
Pro Gly Cys Ser Pro Ser Cys Cys Ala Leu Thr Gln Leu Ser Phe His Thr Ile

1539 1566
TTC CAA CCG ACA GCC TGG AGT GGC ACG AGA ACC TGG GTC ACG GTT CTT TTA CCA
Phe Gln Arg Thr Ala Trp Ser Gly Thr Arg Thr Trp Val Thr Val Leu Leu Pro
Ser Asn Gly Gln Pro Gly Val Ala Arg Glu Pro GDT Ser Arg Phe Phe Tyr Gln
Pro Thr Asp Ser Leu Glu Trp His Glu Asn Leu Gly His Gly Ser Phe Thr Lys

1593 1620
AGA TCT TCT GTG GCG CAG CCG GGA GGT CGT GGA TGG TGA GAC ACA TGA CTC GGA
Arg Ser Ser Val Ala Gln Ala Gly Gly Arg Gly Trp Asp Thr Leu Gly
Asp Leu Pro Trp Arg Arg Arg Glu Val Val Asp Gly Glu Thr His Asp Ser Glu
Ile Phe Arg Gly Ala Gly Gly Arg Ser Trp MET Val Arg His MET Thr Arg Lys

1647 1674
AGT CCT CCT GAA GGT CAT GGA CTC CAG ACA TCA GGA ACT GCA TGG AGT CTT TTC
Ser Pro Pro Glu Gly His Gly Leu Gln Thr Ser Gly Thr Ala Trp Ser Leu Phe
Val Leu Leu Lys Val MET Asp Ser Arg His Gln Glu Leu His Gly Val Phe Ser
Ser Ser Arg Ser Trp Thr Pro Asp Ile Arg Asn Cys MET Glu Ser Phe Leu

1701 1728
TGG AAG CCG CAA GCT TGA TCA AAG TAT CCT ACC CGC TGG TGT TAC TGC
Trp Lys Pro Gln Ala Lys Tyr Pro Thr Arg Thr Trp Cys Tyr Cys
Gly Ser Arg Lys Leu Asp Gln Pro Ser Ile Leu Pro Ala Pro Gly Val Thr Ala
Glu Ala Ala Ser Leu MET Ser Gln Val Ser Tyr Pro His Leu Val Leu Leu His

1755 1782
ACG GCG TCT GCA TGG CTG GAG ACA GCA TCA TGG TGC AGG AAT TTG TGT ATC TAG
Thr Ala Ser Ala Trp Leu Glu Thr Ala Ser Trp Cys Arg Asn Leu Cys Ile
Arg Arg Leu His Gly Trp Arg Gln His His Gly Ala Gly Ile Cys Val Ser Arg
Gly Val Cys MET Ala Gly Asp Ser Ile MET Val Gln Glu Phe Val Tyr Leu Gly

1809 1836
GAG CAA TTG ACA TGT ACC TGC GGA AAG CCG CCA CCT GGT GTC AGC CAG CTG GAA
Glu Gln Leu Thr Cys Thr Cys Ala Thr Arg Pro Pro Gly Val Ser Gln Leu Glu
Ser Asn His Val Pro Ala Gln Arg Gly His Leu Val Ser Ala Ser Trp Lys
Ala Ile Asp MET Tyr Leu Arg Asn Glu Ala Thr Trp Cys Gln Pro Ala Gly Asn

1863 1890
ACT GCA GGT GAC CAA GCA GCT TCA TAT GCC CTT AAC TAC TTG GAG GAC AAA GGC
Thr Ala Gly Asp Gln Ala Ala Tyr Ala Leu Asn Tyr Leu Glu Asp Lys Gly
Leu Gln Val Thr Lys Gln Leu His MET Pro Leu Thr Thr Trp Arg Thr Lys Ala
Cys Arg Pro Ser Ser Cys Ile Cys Pro Leu Leu Gly Gly Gln Arg Pro

1917 1944
CTT CTC ACG GCA ACG TCT CAG CAC GGA ACG TGT TCC TGG CTC GGT AGG GGG GTG
Leu Leu Thr Ala Thr Ser Gln His Gly Arg Cys Ser Trp Leu Val Arg Gly Val
Phe Ser Arg Gln Arg Leu Ser Thr Glu Gly Ala Pro Gly Ser Gly Gly
Ser His Gly Asn Val Ser Ala Arg Lys Val Leu Leu Ala Arg Glu Gly Gly Asp

1971 1998
ATG GGA ATC CAC CTT TCA TTA AGC TGA GTG ATC CTG GTG TCG AGT CCC ACT GTG
MET Gly Ile His Leu Ser Leu Ser Val Ile Leu Val Ser Ser Pro Thr Val
Trp Glu Ser Thr Phe His Ala Glu Ser Trp Cys Arg Val Pro Leu Cys
Gly Asn Pro Pro Phe Ile Lys Leu Ser Asp Pro Gly Val Glu Ser His Cys Ala

2025 2052
CTG AGC CTG GAA ATG CTC ACC GAC AGA ATA CCC TGG TGG CCG CCG AAT GTC TCC
Leu Ser Leu Glu MET Leu Thr Asp Arg Ile Pro Trp Trp Pro Pro Asn Val Ser
Ala Trp Lys Cys Ser Pro Thr Glu Tyr Pro Gly Gly Pro Arg MET Ser Pro
Glu Pro Gly Asn Ala His Arg Gln Asn Thr Leu Val Ala Pro Glu Cys Leu Gln

2079 2106
AGC CTC AGA CAC TCT GCT TGG AGG CTG ACA ACG GGT CTT TGA AGC CAC CAC GTG
Lys Leu Arg His Ser Ala Trp Arg Leu Thr Ser Gly Leu Trp Ser His His Val
Ser Ser Asp Thr Leu Leu Gly Gly Gln Val Gly Phe Gly Ala Thr Thr Trp
Ala Glu Thr Leu Cys Leu Glu Ala Asp Lys Thr Val Leu Glu Phe Thr Arg Met

2137 2164
GAG CTC TTT AAG GGG ACC GGC GGT GAT GAT GAT GAT GAT GAT GAT GAT GAT GAT
Glu Val Phe Thr Gly Thr Arg Pro His His Leu Ala Gly Ala Arg Glu Lys Ala
Arg Cys Ser Arg Gly Pro Ala His Ile Thr Ser Leu Glu Pro Ala Lys Lys Leu
Gly Val His Gly Asp Pro Pro Thr Ser Pro Arg Trp Ser Pro Pro Lys Ser

Gly Leu Leu . . . Lys Phe Tyr Glu Asp Gln . . . Ser Ser MET Arg Thr Arg . . . Ser Cys Pro Leu Ser Asn . . . Gln Asn Trp Arg

2241 2268
GGG ATT TAT CAC CCA GTG CAT GGC GTA TGA TCC TGG CCG GCG CCC CTC CTT CCG
Gly Thr Tyr His Thr Val His Gly Val . . . Ser Trp Pro Ala Pro Leu Leu Pro
Gly Leu Ile Thr Gln Cys MET Ala Tyr Asp Pro Gly Arg Arg Pro Ser Phe Arg
Asp Leu Ser His Ser Ala Trp Arg MET Ile Leu Ala Gly Ala Pro Pro Ser Gln

2295 2322
AGC TAT CCT CAG AGA CCT CAA CGG CCT CAT TAC ATC AGA TTA CGA GCT CCG TCA
Ser Tyr Pro Gln Arg Pro Gln Arg Pro His Tyr Ile Arg Leu Arg Ala Pro Ser
Ala Ile Leu Arg Asp Leu Asn Gly Leu Ile Thr Ser Asp Tyr Glu Leu Pro His
Leu Ser Ser Glu Thr Ser Thr Ala Ser Leu His Gln Ile Thr Ser Ser Leu Ile

2349 2376
TTA CAT CAG ATT ACG AGC TCG NNA GAC CCA CAC CTG CAT CCC GAG TTT CGA GAT
Leu His Gln Ile Thr Ser Ser . . . Asp Pro His Leu His Phe Glu Ser Arg Asp
Tyr Ile Arg Leu Arg Ala . . . Thr His Thr Cys Ile Pro Ser Leu Glu MET
Thr Ser Asp Tyr Glu Leu Ser Arg Pro Trp Pro Ala Ser Arg Val Ser Arg

2403 2430
GAG CTG TGC GTA GCT GGC GCC CAG CTC TAT GGC TGC CAG GAC CCC GCC ATG ATT
Glu Leu Cys Val Ala Gly Ala Gln Leu Tyr Ala Cys Gln Asp Pro Ala MET Ile
Ser Cys Ala . . . Leu Ala Pro Ser Ser MET Pro Ala Arg Thr Pro Pro Phe
Ala Val Arg Ser Trp Arg Pro Ala Leu Cys Leu Pro Gly Pro Arg His Asp Ser

2457 2484
GGA GGA GAG ACA CCT TAA GTA CAT CTT TGG CCG GCA AGG GCA ACT TTG GCA
Arg Gly Glu Thr Pro . . . Val His His Leu Cys Arg Ala Arg Ala Thr Leu Ala
Glu Glu Arg His Leu Lys Tyr Ile Ile Phe Val Gly Gln Gly Gln Leu Trp Gln
Arg Arg Asp Thr Leu Ser Thr Ser Ser Leu Ser Gly Lys Gly Asn Phe Gly Ser

2511 2538
GGG TGG AGC TGT GCC GCT ATG ACC CCG TGG GGA CAA TAC GGG ACC CCT GGT GGC
Ala Trp Ser Cys Ala Ala MET Thr Pro Trp Gly Gln Tyr Gly Thr Pro Gly Gly
Arg Gly Ala Val Pro Leu . . . Pro Pro Gly Asp Asn Thr Gly Pro Leu Val Ala
Val Glu Leu Cys Arg Tyr Asp Pro Leu Gly Thr Ile Arg Asp Pro Trp Trp Gln

2565 2592
AGT GAA ACA GCT ACA GCA CAG CGT GCC AGA CCA GCA GAG GGA CTT CAG CCG GAG
Ser Glu Thr Ala Thr Ala Gln Arg Ala Arg Pro Ala Glu Gly Leu Gln Arg Glu
Val Lys Gln Leu Gln His Ser Val Pro Asp Gln Gln Arg Asp Phe Ser Gly Arg
Asn Ser Tyr Ser Thr Ala Cys Gln Thr Ser Arg Gly Thr Ser Ala Gly Asp

2619 2646
ATT CAG ATC CTT AAG GCT CTG CAC AGC GAC TTC ATC GTC AAG TAC CGG GGA GTC
Ile Gln Ile Leu Lys Ala Leu His Ser Asp Phe Ile Val Lys Tyr Arg Gly Val
Phe Arg Ser Leu Arg Leu Cys Thr Ala Thr Ser Ser Ser Ser Thr Gly Glu Ser
Ser Asp Pro . . . Gly Ser Ala Gln Arg Leu His Arg Gln Val Pro Gly Ser Gln

2673 2700
AGC TAT GGG CCA GGT CGC CAG AGC CTG CGT TGG TGA TGA GAT GCC GCA GGC GGC
Ser Tyr Gly Pro Gly Arg Gln Ser Leu Arg Trp . . . Asp Ala Ala Gly Gly
Ala MET Gly Gln Val Ala Arg Ala Cys Val Gly Asp Gln MET Pro Gln Ala Ala

2727 2754
TTG COT GCG AGA CTT CTG CAG CAT CGC GGC CTG CAC ACC GCG CTA CTG
Leu Pro Ala Arg Leu Leu Gln Arg His Arg Gly Leu His Thr Asp Arg Leu Leu
Cys Leu Arg Asp Phe Cys Ser Ala Ile Ala Ala Cys Thr Pro Thr Ala Tyr Cys
Ala Cys Glu Thr Ser Ala Ala Pro Ser Arg Pro Ala His Arg Pro Pro Thr Ala

2781 2808
CTG TTC GCT TGG CAG ATC TGC AAG GGC ATG GAG TAC CTG GGT GCG CGC CGC TGC
Leu Phe Ala Trp Gln Ile Cys Lys Gly MET Glu Tyr Leu Gly Ala Arg Arg Cys
Cys Ser Leu Gly Arg Ser Ala Arg Ala Trp Ser Thr Trp Val Arg Ala Ala Ala
Val Arg Leu Ala Asp Leu Gln Gly His Gly Val Pro Gly Cys Ala Pro Leu Arg

2835 2862
GTA CAC CGT GAC CTG GCT GCG CGC AAC ATC TTG GTG GAG AGC GAG GCT CAT GTG
Val His Arg Asp Leu Ala Ala Arg Asp Ile Leu Val Glu Ser Glu Ala His Val
Tyr Thr Val Thr Trp Leu Arg Ala Thr Ser Trp Trp Arg Ala Arg Leu MET
Thr Pro Pro Gly Cys Ala Gln His Leu Gly Gly Glu Arg Gly Ser Cys Glu

2889 2916
AAG ATC GCG GAC TTC GGC CTC GCT AAG CTG CTG CCC CTG GGA AAG GAA CTA CTA
Lys Ile Ala Asp Phe Gly Leu Ala Lys Leu Leu Pro Leu Gly Lys Glu Leu Leu
Arg Ser Arg Thr Ser Ala Ser Leu Ser Cys Cys Pro Trp Glu Arg Asn Tyr Tyr
Asp Arg Gly Leu Arg Pro Arg Ala Ala Ala Pro Gly Lys Gly Thr Thr Thr

2943 2970
CGT GGT CCG CGA GCC TGC CAA AGC CCC ATC TTT TGG TAT GCC CCG GAG TCC CTA
Arg Gly Pro Arg Ala Cys Gln Ser Pro Ile Phe Trp Tyr Ala Pro Glu Ser Leu
Val Val Arg Glu Pro Ala Lys Ala Pro Ser Phe Gly MET Pro Arg Ser Pro Tyr
Trp Ser Ala Ser Leu Pro Lys Pro His Leu Leu Val Cys Pro Gly Val Pro Ile

2997 3024
TCT GAC AAC ATC TTC TCC CGC CAA TCT GAC GTG TGG AGA GTT TCG GAG TGG TGT
Ser Asp Asn Ile Phe Ser Arg Gln Ser Asp Val Trp Arg Val Ser Glu Trp Cys
Leu Thr Thr Ser Ser Pro Ala Asn Leu Thr Cys Gly Glu Phe Arg Ser Gly Val
Gln His Leu Leu Pro Pro Ile Arg Val Glu Ser Phe Gly Val Val Leu

3051 3078
TGT ACG AGC TCN NNF NNN NNG CTC ATG CAG CTG TGC TGG GGC GTC CCA GCG CAC
Cys Thr Ser Ser Leu MET Gln Leu Cys Trp Gly Val Pro Ala His
Val Arg Ala Ser Cys Ser Cys Ala Gly Ala Ser Gln Arg Thr
Tyr Glu Leu Ala His Ala Ala Val Leu Gly Arg Pro Ser Ala Arg

3105 3132
TAC CGG CCA GCG TTG GGA CCC TGA GCC CCC AGC TGG ACC CGC TGT GGC GTG GAA
Asp Arg Pro Ala Phe Gly Pro Ala Pro Ser Trp Thr Arg Cys Gly Val Glu
Thr Gly Gln Pro Ser Asp Pro Glu Pro Pro Ala Gly Pro Ala Val Ala Trp Lys
Pro Ala Ser Leu Arg Thr Leu Ser Pro Gln Leu Asp Pro Leu Trp Arg Gly Arg

3159 3186
TAC CCC GGA TAG CAG CCA GGG GCG AGA GGG AGC TGC TGC AGT GGC TAG AGC AGA
Asp Pro Gly Gln Pro Gly Ala Arg Gly Ser Cys Cys Ser Gly Ser Arg
Thr Pro Asp Ser Ser Gln Gly Arg Glu Gly Ala Ala Ala Val Ala Arg Ala Glu
Pro Arg Ile Ala Ala Arg Gly Glu Arg Glu Leu Leu Gln Trp Leu Glu Gln Arg

1
JAK3 M.....APPSEETPLIPQ...CSSESSEAGALHVLPPPPGPPORLSFSFGDYLAEDLCVR...LPVYHSLFALATEDOFSWFFPPSH
JAK2 MGMACLTMEATSTSPYHONGDIPGSANSVKQIEPVLOVLYHSLGOAEGEYLKFFSGEYVAEEICVAASAACGIPYVYHMFALMSETERIWYPPNH
JAK1 MOVLNKEEDCNAMAFCAKMRSEKTEVKQVPEP...GVEVTFYLLOR...EP...LRLGSGEYTAELCIRAAOECISPLCHNLFAVDSTKLWYAPNR
TYK2 MPLRHW.....GMARGSKPVGDGAQPMAGGLKVLHWAAGPGGGEP...WYTFSESSLTAEVCIHIAHKVGIPTPCFNLFAFDAAQVWLPNNH

Con M-----G-EP-L-F-G-Y-AEE-C-AA-CGI-P-HNLFAL-E-W-PPNH

101
JAK3 IFICIEDVDTQVLVYRLRFYFPDWF.....GLETCRHRFLGRKDLTS..AILOLHVLHLEHFAOHRSDLVSGRLPV.....GLSMKEQGEFLSLA
JAK2 VFHIDESTRHOILYRIRFYFPWHY.....CSGSSRTYRGVSRGAEA..PLLODFVMSYLFQWRHOFVHGWIY.....PVTHETOEECLGMA
JAK1 IITVDDKTSRLRLHYMRMFYFTNWHQTDNEQSVWRHSPKKOKNGYEKKRVPEATPLLOASSLEYLFAQGOYDLIKFLAPIRDPKTEQDQDHIENECLGMA
TYK2 ILEIPROASLMLYFRIRFYFRNWHGMNPREPAVYRCGPPGTEASSDOT...AOGMOLLOPASFEYLFEOQKHEFVNDVASLWELSTEEEIHHFKNESLQMA

Con I-I-----L-YR-RFYF-W-----LLO-----EYLFQO-----D-V-----H-----E-LGMA

201
JAK3 VLDAQMAREQAORPGELLKTVSYKACLPPLSRDVIQONFVTRRRIR...RTVVLALLP...CGRLPGRPYALMAKYIOLERLHPAATTETFRV...
JAK2 VLDMMRIAKEQDQTPPLAVYNSVSYKTFPLKCVRAKIQDYHILTRKIRYRFRFRFQQFSO...CKATARN...LKLKYLINLETLOSAYTEQFEV...
JAK1 VLAISHYAMKKMQLPELPKDISYKRYIPETLNKSIQRNLLTRMIRNNVFKDFLEKFNKTKICDSSVSTH..OLKVKYLATLETLTKHYGAEIFETS...M
TYK2 FLHLCHLALRHGIPLEEVAKKTSFKDCIPRSFRRHIRQHSALTRLRLRNVRFRFLRDFOP...GRLSQO...MYMVKYLATLERLAPRFGTERVPVCHLR

Con VL-----A-----E-K-SYK-P-R-I-----LTA-RIR-FR-F-F-----C-----L-KYL-LE-L-----TE-F-V-----

301
JAK3GL.....PGAQEEPQL.....LRVAGDNGIPW.....SS...ND.ELF.....OT.....FCDFP
JAK2KESAROPSGEEIFAT.....IITGNQGIOW.....SROKHKESLTLTEQDVOL.....YCDFF
JAK1 LLISSENELSRCHSND.....SGNVLYEVMVTGNLGIOWRQKPNVVPVEKKN.....KLKRRKLEYNNKHKODERNKREE..WNNFSYFP
TYK2 LLAQAEGEPCYIRDSGVAPTDPGPESAAGPPTHEVLVTGTGGIOWWPVEEYNNKEGSSGSRNPQASLFQKKAKAKHAFQGPADRPREPLWAYFCDFR

Con -----P-----VTG-GGIOW-----S-----FCDFP

401
JAK3 EIVDVSINQAPRYGPAGEHRLVTVTMRQGHILEAEFFGLPEALSFFVALVDGYFRLICDSRHYFCKEVAPPRLEEEADVCHQPIITLDFAIHKLKAAGSLP
JAK2 OIIDVSIKANO.ECSNESRIITVHKODGKVLIELSSLKEALSFFVSLIOGYRLTADAHHYLCKEYVAPPVLENIHSNCHGPIISMDFAISKLLKAGNQT
JAK1 EITHIVIKE.....SVVSIKODNKNMELKLSREEAALSFFVSLVDGYFRLTADAHHYLCTDVAPPLIHNIONGCHQPICTEYAINKLKROEGSEE
TYK2 DITHVYLKE.....HCVSIKRODNKCLELSLPSRAAALSFFVSLVDGYFRLTADSSHYLCHEVAPPRLVMSIRDINGPLLEFPVQAKLR...PED

Con I-V-IK-----V-----QD-K-LE-L-S-----EALSFVSLVDGYFRLTAD--HYLC-EVAPP-----I-CHQPI-I-KL--G--

501
JAK3 GTYILRRSPDYDSFLLTA.CVQTPGLPDYKGLIRQD.....PSGAFSLVGLSOPHRSRLRELLAACWN..SGLRVDAALYLTSCCAPRPKEKSNLIVVR
JAK2 GLYVLRCSPKDFNKYFLTF.AVERENVIEYKHLITKN.....ENGEYNLSGTRKRNFSNLKDLN..CYOMETVRSDSITFQTKCCPPKPKOKSNLLVFR
JAK1 GMYVLRWSCOTFONILMTVTCEKSE..VLGGOK..QFKNFOIEVOKGRYSLHGSMDHFFSLRDLWNH..LKKQILRTDNISFVLKRCQCPKPREISNLLVA.
TYK2 GLYLIHWSTSHPYRLITVA...QRSQAPDGMOSLRLRKFFIEQDQAGFVLEGWGRSFPVSRELGA..LQGCLLRAGDQCFSLRRCCLPQGETSNLIIM.

Con G-Y-LR-S-D-----LT-----L-----G-----L-G-----F-SLR-L-----LR-D-----F-L-CC-P-P-E-SNL-V--

601
JAK3 .RGCPNAPAPGCSPSCCALTQSFHTIPTDSLEWHENLHGHSFTKIFRGSRRR.....VVD.GETHDSEVLLKVMOSRRHNCMESF
JAK2 TNGISDVQISPTLQRHNNVNOMVFKIRNEDLIFNESLGQGTFTKIFKGVRRE.....VGDYGLHKTTEVLLKVLQKARNHNSYSEF
JAK1TKKAQEWQPVYMSLSLDFORILKDDIIOGHLGRGTRTHIYSGTLLDYKQEGIAEKKI.....KVILKVLDPSHRDIALAF
TYK2RGARASPTLNLSQLSFHRVQOKEITQLSHLGQGTTRTHYEGRLV...EGSGOPEEGKVDDEPLVPGDRQGLERVLKVDPSHHOIALAF

Con -----QLSFH-I-----E-LG-GT-T-I-G-R-----V-----V-LKVLD--HR-----F

701
JAK3 LEAASLSQVSYPHVLVLLHGVCMAGD..SIMVQEFVYLGAIOMYLKRGHVLVSAWKLQVTKQALAYALNYLEDKGLPHGNVSARKVLLAREGG...DGNPPF
JAK2 FEASMSMSLSHKLVLVNGVVCVCGEENILVQEFVKFGSLDTYLLKNNKNSINILWLKGLVAKQLAWAHFLEEKSLIHGNVCAKNILLIREEDRTGNPPF
JAK1 FEASMSMSVSHKHIVLYLGVVCRDVENIMVEEFVVEGGLDLMFMRKSOALTTPWKFKVAKQLASALSYLEDKDLVHGNVCTKNLLAREGIO..SDIGPF
TYK2 YETASLSMSVSHTHLAFVHGVVCRGPNEMVTEYVEHGPLOVLLRRERGHVPMAMKVVAAQOLASALSYLENKNLVHGNVCGRNILLARLGLA.EGTSPP

Con -EAAS-MSQVSH-HLV---GVCV-G-ENIMV-EFV--G-LD-----WK--VA-QLA-AL-YLE-K-L-HGNVC--N-LLAREG---G--PF

801
JAK3 IKLSDPGVSPTVLSLEMLTDRIPIWVAPECL..QEAOTLCLEADKWGFATTWEVFORGPAHITSLEPAKKLFYEQDQGLPALKWTELAGLITQCMAYDPG
JAK2 IKLSDPGISITVLPKDILQERIPWVPECI..ENPKNLNLADTKWFSGTTLWEICSGGDKPLSALDSORKLQFYEDKHOLPAKWTELANLINNMDYEPD
JAK1 IKLSDPGIPSVLTRAQECIERIPWIAPECV..EDSKNLVAAADKWSFGTTLWEICYNGEIPLKDKTLIEKERFYESRCRPVTPSCKELADLMTRGMNDPN
TYK1 IKLSDPGIGLGAISREERVERIPWLAPECLPGGANSLSAMDKWGFATLLEICFQGEAPLOSRSPEKEHFYQROHRLPEPSCPQLATLSQCLTYEPT

Con IKLSDPGI---VL-----ERIPW-APEC-----L--A-DKW-FG-TLWEIC--G--PL-----K--FYE-----LP-P---ELA-L---CM-Y-P-

901
JAK3 RRPFSFRAILRDLNGLITSDYELLSDPTGPISPRDELVAGAAQLYACODPAIFERRHLKYISLLGKGNFGSVELCRYDPLGONTGPLYAVKQLQ.HSVPO
JAK2 FRPAFRAYIRDLNLSLFTPDYELLTENOM..LPNMRIGALGF..SGAFEDROPTQFEERHLKFLQOLGKGNFGSVEMCRYDPLQDNTGEVAVKKLO.HSTEE
JAK1 QRPFFRAIMRDINKLEEON..PDIVSEKOP.....TTEVOPTHFEKRLKRIRDLGEGHFGKVELCRYOPEQDNTGEQVAVKSLKPESGON
TYK2 QRPFSRTILRDLTRYOPHNLAOVLTVNRDSP.....A.VGPTTFHKRYLKKIRDLGEGHFGKVSLYCYDPTNDGTGEMVAVKALKADCGPO

Con -RP-FRAI-RDLN-L-----P-----PT-FE-R-LK-I--LQ-G-FG-VELCRYD--DNTQE-VAVK-L--S--

1001
JAK3 QQRDFQREIQILKALHSOFIVKYRGVSYGPGRQSLRLVMEYLPSSGLRDLLQRRHQ..LHTDRLLFAWOICKGMEYLGARRCYVRDLAARNILVESEAHV
JAK2 HLROFEREIEILKSLOHONIVKYKGVCYSAGRRNLRLIMEYLPYGLRDYLOKHKERIDHKKLLQYTSOICKGMEYLGTRKYIRHDLATRNILVENENRV
JAK1 HIAOLKKEIEILANLYHENIVKYKGICMEDQGNIGKILMEFLPSGSLKEYLPKNNKNIKOLKLYAIOICKGMOYLGSRQYVHRDLAARNVLVESEHVV
TYK2 HRSQWQOEIDILRLTYHEHIIVKYKGCCEDQGEKSLQVLMEYVPLGSLRDYLRHS...IGLAOLLLFAQOICGEMAYLHANDYIRHDLAARNVLDONRLV

Con H--D--E-I-IL-L-H--IVKYKG-C--G--L-L-MEYLP-GSLRDYL-H--I--LL--A-QICKGM-YLG---Y-HRDLAARN-LVE-E--V

1101
JAK3 KIAQFGLAKLLPLGKDYVYVREPGQSPIFWYAPESLSNIFSRQSDVWSFGVVLVELFTYCDKSCSPSAEFLRMMPEREQPPLC..RLLELLAEGRRLPP
JAK2 KIGDFGLTKVLPQDKKEYYKKEPGESPIFWYAPESLTSKFSVASOVWSFGVVLVELFTYIEKSKSPPEFMRMIGNDKOQOMIVFHLIELLKSNGRLPR
JAK1 KIGDFGLTKAIEIDKKEYYTVKDDRDSPVFWYAPESLTSKFSVASOVWSFGVVLVELFTYIEKSKSPPEFMRMIGNDKOQOMIVFHLIELLKSNGRLPR
TYK2 KIGDFGLAKAVPEGHEYYRVEDGSDPVFWYAPESLTSKFSVASOVWSFGVVLVELFTYIEKSKSPPEFMRMIGNDKOQOMIVFHLIELLKSNGRLPR

Con KIGDFGL-K--P--KEYY-V-E-G-SP-FWYAP-E-L--KF--ASOVWSFGV-LYEL-TYCD-S-SP---FL-MIG---GOM-V-RL-ELL--G-RLP--

1201
JAK3 PPTCPTVEQELMOLCWAPEHDPAPAFATLSPOLDPLW.RG.....RPG*
JAK2 PEGCPDEIYVIMTECWNNNVSQRPSFRDLSFG...WIKS.....GTV*
JAK1 PNCPDEVYQLMRAKCKEWFOPSNRTTFQNLIEGFEALLK*
TYK2 PDKCPCPEVYHLMKNOWETEASFRPTFENLIPILKTVHEKYQQGAPSVSFVC*

Con P--CP-EVY-LM--CW---S-RP-F--L-----

check new
see 070621.01
in our page

original in
our sigi document
Ile

RECEIVED

AUG 3 0 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

IHLE *et al.*

Appl. No. 08/665,574

Filed: June 18, 1996

For: **Jak Kinases and Regulation of
Cytokine Signal Transduction**

Art Unit: 1819

Examiner: Hauda, K.

Atty. Docket: 0656.0370002/SLF/LBB

**Declaration of Bruce A. Witthuhn and James N. Ihle
Under 37 C.F.R. § 1.131**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

1. We, Bruce Witthuhn and James Ihle state that we are two of the named applicants of the above-captioned application and are co-inventors of the subject matter described and claimed therein.
2. Prior to April 1994, we and Dr. Ollie Silvennoinen reduced to practice in the U.S., the invention of the above-captioned application.
3. Said reduction to practice concerns at least those embodiments of the claimed invention that are related to DNA molecules comprising a DNA sequence encoding an amino acid sequence of a Jak3 kinase peptide and a vector or host comprising said DNA.
4. Prior to April 1994, two clones were obtained that were labeled as B1.1 and B3.1. *In vitro* translation experiments with T3 and T7 primers indicated that clone B3.1 was a partial clone and B1.1 was a full-length clone corresponding in length to other previously identified Jaks. *See* the third lane labeled as B1.1 T₃. (**Exhibit A**)
5. Following additional analysis completed prior to April 1994 it was established that the mJak3 expressed product could be competed out with a specific peptide to Jak3, thereby further supporting the assumption that a full length clone had been obtained. For example, *See Exhibit B*.

7. Upon information and belief, prior to April 1994, partial sequencing of subclones from B1.1 was completed by Dr. Silvennoinen. **(Exhibit C)**.

8. Following the partial sequencing of the B1.1 subclones, a full length mJak3 sequence of clone B1.1. was obtained prior to April, 1994. A working copy of this sequence is provided as **Exhibit D**.

9. Upon information and belief, prior to April 1994 a figure containing the complete amino acid sequence encoded by the full-length DNA of mJak3 was prepared by the Biomedical Communications Department at St. Jude. **(Exhibit E)**.

10. All of the above results demonstrate that prior to April 1994, a full-length clone containing the mJak3 sequence had been obtained.

11. The attached are true and accurate photocopies (with dates blanked out) of pages taken from the notebooks or other sources of the inventors or those individuals supervised by the inventors.

12. We further state that all statements made are to our knowledge true and that all statements made on information and belief are believed to be true and further that willful false statements and the like are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the U.S. Code and may jeopardize the validity of the application or any patent issuing thereon.


Date

FEB. 22, 1999

Date
FEB. 22, 1999

PAUSERS\LARRYB\RECENT\656372.doc

Bruce A. Witthuhn


James N. Ihle

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

IHLE *et al.*

Serial No. 08/665,574

Filed: June 18, 1996

For: **Jak Kinases and Regulation of
Cytokine Signal Transduction**

Art Unit: 1819

Examiner: K. Hauda

Atty Docket: 0656.0370002/SLF/LBB

**Declaration Concerning Witthuhn *et al.*,
“Involvement of the Jak-3 Janus Kinase in Signaling by Interleukins 2
and 4 in Lymphoid and Myeloid Cells.” *Nature* 30:153-157, July 1994.**

Honorable Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

The undersigned, James N. Ihle, Bruce A. Witthuhn and Olli Silvennoinen each declare
and state:

1. We are co-inventors of the subject matter described and claimed in the above-captioned patent application.
2. Each of us contributed to the conception of at least one pending claim in the invention of the above-captioned application.
3. We are also co-authors of the publication: Witthuhn *et al.* “Involvement of the Jak-3 Janus Kinase in Signaling by Interleukins 2 and 4 in Lymphoid and Myeloid Cells.” *Nature* 30:153-157, July 1994.

4. The additional authors on the Witthuhn *et al.* publication (i.e. Osamu Miura, Koon Siew Lai, Christopher Cwik and Edison T. Liu) are not co-inventors and were either individuals working under the direction and/or supervision of at least one of the inventors of the above-referenced application or provided materials used in the publication.

5. The following co-authors of the publication contributed to said publication as follows:

- a) Osamu Miura provided CTLL cells expressing the Epo receptor and was not involved in conception of the invention of the above-referenced application
- b) Koon Siew Lai provided a PCR derived DNA fragment encoding a Jak and was not involved in conception of the invention of the above-referenced application.
- c) Christopher Cwik provided technical support for the studies and was not involved in conception of the invention of the above-referenced application.
- d) Edison T. Liu provided a PCR derived DNA fragment encoding a Jak and was not involved in conception of the invention of the above-referenced application

6. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like

so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,


Dated: _____

James N. Ihle

Dated: _____

Bruce A. Witthuhn

Dated: May 20th, 1998
65603702.dec


Ollie Silvennoinen